JP2019510788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510788A5 JP2019510788A5 JP2018552659A JP2018552659A JP2019510788A5 JP 2019510788 A5 JP2019510788 A5 JP 2019510788A5 JP 2018552659 A JP2018552659 A JP 2018552659A JP 2018552659 A JP2018552659 A JP 2018552659A JP 2019510788 A5 JP2019510788 A5 JP 2019510788A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amb
- cholesterol
- hydrate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 60
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 41
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 41
- 229960003942 amphotericin b Drugs 0.000 claims description 41
- 235000012000 cholesterol Nutrition 0.000 claims description 38
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 11
- 239000000443 aerosol Substances 0.000 claims description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 108010039491 Ricin Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 56
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320111P | 2016-04-08 | 2016-04-08 | |
| US62/320,111 | 2016-04-08 | ||
| US201662320795P | 2016-04-11 | 2016-04-11 | |
| US62/320,795 | 2016-04-11 | ||
| PCT/US2017/026806 WO2017177228A1 (en) | 2016-04-08 | 2017-04-10 | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510788A JP2019510788A (ja) | 2019-04-18 |
| JP2019510788A5 true JP2019510788A5 (https=) | 2020-04-30 |
| JP7041961B2 JP7041961B2 (ja) | 2022-03-25 |
Family
ID=60001496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552659A Active JP7041961B2 (ja) | 2016-04-08 | 2017-04-10 | ヒト嚢胞性線維症肺上皮における気道表面の生理機能の小分子介在性回復 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190083517A1 (https=) |
| EP (1) | EP3439668B1 (https=) |
| JP (1) | JP7041961B2 (https=) |
| AU (1) | AU2017248394B2 (https=) |
| DK (1) | DK3439668T3 (https=) |
| ES (1) | ES2983639T3 (https=) |
| FI (1) | FI3439668T3 (https=) |
| PT (1) | PT3439668T (https=) |
| WO (1) | WO2017177228A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3439668B1 (en) | 2016-04-08 | 2024-06-19 | The Board of Trustees of the University of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
| FI3694526T3 (fi) | 2017-10-11 | 2025-02-06 | Univ Illinois | Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| CA2194049A1 (en) | 1994-06-28 | 1996-01-11 | Georgi Stankov | Novel clinical uses of polyene macrolides |
| TWI249408B (en) * | 2003-12-10 | 2006-02-21 | Ind Tech Res Inst | New antifungal formulation and manufacturing method thereof |
| AU2005251745A1 (en) * | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| WO2009006311A2 (en) * | 2007-06-29 | 2009-01-08 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| EP2488160B1 (en) * | 2009-10-16 | 2020-07-01 | Lifecare Innovations Pvt. Ltd. | Liposomal amphotericin formulation comprising cholesterol for treating fungal infections |
| KR102548341B1 (ko) * | 2013-10-07 | 2023-06-26 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 개선된 치료 지수를 갖는 암포테리신 b 유도체 |
| JP6796581B2 (ja) * | 2014-11-04 | 2020-12-09 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | ミッシングタンパク質の小分子模倣体を用いた生理機能の回復 |
| EP3439668B1 (en) | 2016-04-08 | 2024-06-19 | The Board of Trustees of the University of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
-
2017
- 2017-04-10 EP EP17779973.1A patent/EP3439668B1/en active Active
- 2017-04-10 US US16/091,599 patent/US20190083517A1/en not_active Abandoned
- 2017-04-10 ES ES17779973T patent/ES2983639T3/es active Active
- 2017-04-10 FI FIEP17779973.1T patent/FI3439668T3/fi active
- 2017-04-10 PT PT177799731T patent/PT3439668T/pt unknown
- 2017-04-10 DK DK17779973.1T patent/DK3439668T3/da active
- 2017-04-10 JP JP2018552659A patent/JP7041961B2/ja active Active
- 2017-04-10 AU AU2017248394A patent/AU2017248394B2/en active Active
- 2017-04-10 WO PCT/US2017/026806 patent/WO2017177228A1/en not_active Ceased
-
2021
- 2021-06-01 US US17/335,803 patent/US11850256B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323384A1 (en) | Niclosamide formulations for treating disease | |
| ES2493641T3 (es) | Administración nasal de soluciones acuosas de corticosteroides | |
| US20230190685A1 (en) | Formulation | |
| CN102159244A (zh) | 包含减充血剂和皮质类固醇的鼻内组合物 | |
| JP2014525471A (ja) | 咳および咳発作の治療 | |
| JP2019510788A5 (https=) | ||
| AU2008241045B2 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| JP7544466B2 (ja) | エラスターゼ阻害活性を有するベータヘアピンペプチド模倣体及びそのエアロゾル剤形 | |
| US20150034087A1 (en) | Low Dose Pharmaceutical Composition Comprising Zanamivir | |
| US20230277636A1 (en) | Composition comprising highly-concentrated alpha1 proteinase inhibitor and method for obtaining thereof | |
| JP7811616B2 (ja) | 急性増悪をポリクローナル免疫グロブリンで予防または治療するための方法および組成物 | |
| TW202133882A (zh) | 肽與多醣的新共軛物 | |
| JP4457422B2 (ja) | 点鼻組成物 | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| US12440488B2 (en) | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| TW202602487A (zh) | 呼吸系統疾病的治療與預防 | |
| WO2024192149A3 (en) | Method of treating enterovirus in chronic obstructive pulmonary disease patients | |
| HK40093168A (zh) | 具有弹性蛋白酶抑制活性的β-发夹肽模拟物及其气雾剂剂量形式 |